Immune Pharmaceuticals Inc  

(Public, NASDAQ:IMNP)   Watch this stock  
Find more results for IMNP
0.602
+0.014 (2.38%)
After Hours: 0.600 0.000 (0.00%)
Jan 18, 5:59PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.58 - 0.61
52 week 0.50 - 5.02
Open 0.58
Vol / Avg. 0.00/1.17M
Mkt cap 10.78M
P/E     -
Div/yield     -
EPS -3.00
Shares 17.90M
Beta 2.59
Inst. own 2%
Nov 15, 2017
Q3 2017 Immune Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -108.58% -118.15%
Return on average equity -10982.12% -783.23%
Employees 9 -
CDP Score - -

Address

550 Sylvan Ave Ste 101
ENGLEWOOD CLIFFS, NJ 07632-3115
United States - Map
+1-201-4642677 (Phone)
+1-917-3981915 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Officers and directors

Elliot M. Maza J.D., CPA President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Secretary, Director
Age: 61
Bio & Compensation  - Reuters
Anthony Fiorino M.D. Ph.D. Chief Operating Officer, Chief Medical Officer
Bio & Compensation  - Reuters
John Clark Controller
Bio & Compensation  - Reuters
Cameron Durrant M.D. Lead Independent Director
Age: 54
Bio & Compensation  - Reuters
Daniel G. Teper Pharm.D. Director
Age: 55
Bio & Compensation  - Reuters
John A Neczesny Independent Director
Bio & Compensation  - Reuters
Jeffrey Paley M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters